TFF3 (Trefoil factor 3)

This multi-omics network analysis reveals a shared molecular framework between IBD and CRC, with inflammation as a key driver of colorectal carcinogenesis.

This study highlights the potential application of taurine as a therapeutic agent for treating GIM, offering a promising strategy for its clinical management.

Conversely, SOX4 also acts as an oncogene, and TFF3 as a potential tumor suppressor, both linked to OS. Targeting CCND1 and its OS-mediated regulatory pathways offers a promising therapeutic strategy for PTC.CCND1, oxidative stress, papillary thyroid carcinoma, single-cell RNA sequencing, SOX4, TFF3.

This article highlights major advances in molecular biomarkers for BE, such as the Cytosponge-TFF3 test, methylated DNA markers, p53, aneuploidy, and other emerging biomarkers. Their integration into clinical practice may transform esophageal cancer detection and prevention by enabling precision screening and surveillance and by broadening access to care.

Furthermore, the antimigratory effect of 6-mercaptopurine was reversed by TFF3 overexpression, confirming the functional specificity of this drug-target interaction. Notably, tumors with high TFF3 expression (TFF3hi) exhibited elevated resistance to PD-1 inhibitors but heightened sensitivity to MAPK inhibitors, suggesting a potential theranostic framework for ALNM stratification.

These findings suggest that TFF3 may drive the early stages of gastric cancer, although the precise regulatory mechanisms involved remain to be fully elucidated. Additionally, this research may provide valuable insights into the mechanisms underlying other precancerous lesions and related malignancies.

Luminal Androgen Receptor and Molecular Apocrine Breast Cancers constitute a single molecular entity within estrogen receptor-negative breast cancers. The validated four-gene signature enables robust clinical identification and may guide future therapeutic stratification.

This combination also exhibited synergistic improvement in colitis severity in treated mice. These findings underscore the therapeutic potential of B. thetaiotaomicron in IBD, either alone or in combination with infliximab, and support further development of microbiota-based strategies for IBD prevention and treatment.

Moreover, we discovered that TFF3 administration antagonized protective effects of IL-6 stimulation against tumor-killing capacity of cisplatin. Based on these findings, we consider that TFF3 may be employed as a cisplatin sensitizer and have advantages over traditional chemotherapeutic drugs in cisplatin-based combination therapy, since it is a naturally occurring protein in cervical tissue.

Some of the best characterized and promising biomarkers for managing BE are multi-target esophageal cytology DNA assays based on methylated-DNA and immunohistochemical staining of Trefoil factor 3. Additional biomarkers including microRNA, measures of genomic instability, mixed-method panels, and other novel biomarkers (e.g. volatile organic compounds and saliva microbiome) remain in early development and will need further validation in large, prospective studies prior to clinical use.

FOXO1 fusion status influences RMS clinical outcomes, including rare FP-ERMS cases. scRNA-seq combined with drug screening identified MET as a promising therapeutic target in FP-RMS.

Our differential gene and signaling pathway analysis revealed the potential tumor-promoting mechanisms. These insights may offer new perspectives for clinical strategies targeting macrophages or the tumor microenvironment to treat brain metastasis of lung cancer.